Hybrid immunity plasma protection against Delta variant

PRIMARY OUTCOME

Clearance of infectious SARS-CoV-2 Delta from lungs

EXPECTED OUTCOMES

- 1. Both plasma pools demonstrate similar Delta-specific binding antibody titers (within 2-fold, ~1:10,000-1:50,000 endpoint titers) and neutralization activity (IC50 values within 2-fold, ~1:100-1:500) - 2. Hybrid immunity plasma completely clears infectious Delta virus from lungs with viral loads below detection limit (<100 copies/g tissue) in >80% of mice - 3. Vaccination-only plasma provides minimal protection despite equivalent in vitro neutralization, with only 0.5-1 log reduction in viral loads compared to controls - 4. Strong inverse correlation between lung viral loads and circulating antibody levels at time of challenge (r>-0.6, p<0.01) - 5. Hybrid immunity-protected mice show significantly reduced lung inflammation scores and lower inflammatory cytokine levels (2-3 fold decrease in IL-6, TNF-α) - 6. Enhanced Fc effector functions (ADCC, ADCP) detected in hybrid immunity plasma compared to vaccination-only plasma, correlating with in vivo protection - 7. Consistent protection efficacy across male and female mice with reproducible results in independent validation cohort

SUCCESS CRITERIA

- • Plasma characterization: Both pools demonstrate equivalent neutralization titers (within 2-fold difference, p>0.05 by unpaired t-test) to validate study design - • Protection efficacy: Hybrid immunity plasma reduces lung viral loads by >3 logs vs controls (p<0.001, one-way ANOVA with Tukey's post-test) - • Differential protection: Significant difference between hybrid and vaccination-only plasma groups (>2 log difference, p<0.01) - • Viral clearance: >70% of hybrid immunity-treated mice achieve viral loads below quantification limit (100 copies/g tissue) - • Clinical improvement: Significant reduction in clinical scores and maintenance of body weight in protected groups (p<0.05, repeated measures ANOVA) - • Assay performance: qPCR efficiency 90-110% with standard curve R²>0.99, plaque assay CV <20% for duplicate measurements - • Reproducibility: Primary findings confirmed in independent experiment with same plasma pools and similar magnitude of effects

PROTOCOL

**Phase 1: Human Plasma Collection and Characterization** -- Days 1-14 Obtain IRB-approved pooled human plasma samples from two cohorts: hybrid immunity (vaccination + Delta infection, n=10 donors) and vaccination-only (2-3 doses mRNA vaccine, no infection, n=10 donors). Collect samples 2-6 months post-vaccination or post-infection. Heat-inactivate plasma at 56°C for 30 minutes to eliminate complement. Characterize plasma by measuring total IgG concentration (nephelometry), Delta spike-specific binding antibodies (ELISA using recombinant Delta spike protein), and neutralizing antibody titers (plaque reduction neutralization test with Delta variant, PRNT50/90). **Phase 2: In Vitro Neutralization Validation** -- Days 15-21 Confirm plasma neutralization capacity using both pseudovirus and authentic virus assays. Perform pseudovirus neutralization with Delta spike-pseudotyped VSV on Vero-E6 cells. Conduct authentic virus neutralization using SARS-CoV-2 Delta variant (B.1.617.2) in BSL-3 facility. Test plasma dilutions from 1:10 to 1:10,240. Calculate IC50 and IC90 values using four-parameter logistic regression. Ensure both plasma pools show similar neutralization titers (within 2-fold difference) to validate equivalent in vitro activity. **Phase 3: Passive Transfer Protocol Development** -- Days 22-28 Optimize plasma transfer protocol using TKI mice. Test plasma volumes of 100-500 μL per mouse (corresponding to 5-25 mL/kg) administered intravenously or intraperitoneally. Monitor circulating human IgG levels by ELISA at 1, 6, 24, and 48 hours post-transfer to determine optimal dose and timing. Establish that 200 μL plasma (equivalent to ~10 mL/kg) provides circulating antibody levels of 50-200 μg/mL, approximating therapeutic concentrations. **Phase 4: Viral Challenge Study Design** -- Days 29-35 Randomize 8-10 week old male and female TKI mice into treatment groups (n=12 per group based on power analysis for detecting 2-log difference): vehicle control (200 μL normal human plasma), hybrid immunity plasma, and vaccination-only plasma. Administer plasma 24 hours before viral challenge to allow antibody equilibration. Challenge mice intranasally with 10^4 PFU SARS-CoV-2 Delta variant under isoflurane anesthesia. Include positive control group with established protective monoclonal antibody. **Phase 5: Viral Load Assessment and Clinical Monitoring** -- Days 36-42 Monitor mice twice daily for clinical signs using standardized scoring system (0-5 scale for activity, appearance, breathing). Measure body weight daily. Sacrifice mice at 3 days post-infection (peak viral replication timepoint). Harvest lungs aseptically and homogenize in PBS using mechanical homogenizer. Quantify viral RNA by RT-qPCR targeting N gene (CDC primers) and infectious virus by plaque assay on Vero-E6 cells. Calculate viral loads as log10 copies or PFU per gram lung tissue. **Phase 6: Mechanistic Analysis and Validation** -- Days 43-49 Analyze lung tissue by histopathology with H&E staining to assess inflammation and viral pneumonia. Perform immunofluorescence staining for SARS-CoV-2 nucleoprotein to visualize infected cells. Measure inflammatory markers (IL-6, TNF-α, IFN-γ) in lung homogenates by multiplex cytokine assay. Correlate protection with plasma antibody characteristics including avidity (measured by chaotropic elution), Fc effector function profiles (ADCC, ADCP assays), and epitope specificity (peptide microarray). Repeat key findings in independent cohort of mice.

HTML iframe

<iframe src="http://scidex.ai/artifact/exp-3f8198b1-5587-4e21-b24a-295dc81bdd35?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Hybrid immunity plasma protection against Delta variant](http://scidex.ai/artifact/exp-3f8198b1-5587-4e21-b24a-295dc81bdd35)

Direct URL

http://scidex.ai/artifact/exp-3f8198b1-5587-4e21-b24a-295dc81bdd35

Preview